Agilent completes $950 million Biocare acquisition

• Agilent completed its previously announced acquisition of Biocare Medical.
• Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.
• Agilent said the deal is expected to support growth, margins, and non-instrument revenue mix.

Agilent Technologies (NYSE:A) completed its previously announced $950 million acquisition of Biocare Medical, adding the clinical pathology company to its Life Sciences and Diagnostics Markets Group.

The deal follows Agilent’s March 2026 agreement to acquire Biocare from an investor group led by Excellere Partners and GHO Capital Partners LLP.

“We are pleased to complete our acquisition of Biocare, which represents a natural and strategic expansion of Agilent’s pathology portfolio,” said Agilent President and CEO Padraig McDonnell.

Agilent said it continues to expect the acquisition to be accretive to top-line growth rate, margin profile, and non-instrument revenue mix in the first year.

Following the announcement, Agilent's share price was up at $131.63.

Agilent said the acquisition is expected to become accretive to EPS about 12 months after closing, with the expected FY2026 impact to be provided in its third-quarter earnings release.

Biocare adds clinical and research pathology products to Agilent’s diagnostics business as the company continues investing in pathology, customer-focused innovation, and recurring revenue opportunities.